Literature DB >> 12925098

Antibiotic resistance of Helicobacter pylori: a cross-sectional study in consecutive patients, and relation to ethnicity.

R J L F Loffeld1, C A P M J Fijen.   

Abstract

OBJECTIVES: To assess primary antibiotic resistance in a given population and relate the results to ethnicity.
MATERIALS AND METHODS: Consecutive cultures were tested for antibiotic susceptibility with the Etest. Three populations were studied separately: ethnic Dutch people, patients of Turkish descent, and patients originating from Africa and the Middle East.
RESULTS: Over a period of 5.5 years, 976 (32%) biopsy specimens from 3010 patients were positive for Helicobacter pylori. Metronidazole and clarithromycin resistance were present in 25.8% and 4.8% of the strains, respectively. The number of metronidazole-resistant strains showed a gradual decrease, while clarithromycin resistance showed a slight increase during the study period. Antimicrobial resistance in patients of Turkish descent and in those originating from Africa or the Middle East was significantly higher than in ethnic Dutch people, 35% and 9.1% versus 21% and 2.9%, respectively (P = 0.003 and P = 0.002).
CONCLUSION: It is important to take ethnicity into account when studying antibiotic resistance. The numbers of metronidazole- and clarithromycin-resistant strains can vary considerably between people of different ethnic origin living in the same region.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12925098     DOI: 10.1046/j.1469-0691.2003.00553.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  2 in total

1.  Seroprevalence of Helicobacter pylori among children in Sana'a, Yemen.

Authors:  Hassan A Al-Shamahy
Journal:  Ann Saudi Med       Date:  2005 Jul-Aug       Impact factor: 1.526

2.  Changes in Antibiotic Susceptibility of Helicobacter pylori in the Course of Eight Years in the Zaanstreek Region in The Netherlands.

Authors:  R J L F Loffeld; B F M Werdmuller
Journal:  Gastroenterol Res Pract       Date:  2013-03-12       Impact factor: 2.260

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.